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EDITORIAL
Dear Readers and Colleagues, 
The year is certainly progressing and the second edition of our 
journal not only confirms that winter (of discontent for some) is 
soon to pass but also that the warmer and friendlier disposition 
of spring (for most) will be at hand. Our journal has likewise 
basked in this improved climate of continued growth and this 
success has necessarily placed more demands on its panel of 
reviewers both those that are thankfully efficient and obliging 
and also those who are equally, if not more efficient at being 
non-obliging. I must also offer respectful and sincere gratitude 
to the ever growing number of foreign and local authors who 
submitted manuscripts to JEMDSA for consideration. 
JEMDSA will always strive to be relevant and inclusive. As such 
it will offer a wide breath of information within a wide breath 
of disciplines. The 53rd SEMDSA Congress (Cape Town, 1 to 4 
December 2018) is on the horizon and will be co-hosted with the 
18th ICE (International Congress of Endocrinology). This seminal 
duet will feature 200 speakers, 7 parallel sessions and almost 900 
abstracts and presentations and will attest to this international 
and local collaboration of building the South African rainbow of 
endocrinology. JEMDSA will host these proceedings in one of its 
forthcoming issues. 
Our current edition spans many disciplines and offers new 
insights to a number of clinical challenges and to more 
basic aspects of insulin pharmacology. Greeff O et al (in their 
second part of two articles) explain the utility of the glucose 
clamp technique to investigate the pharmacokinetic and 
pharmacodynamic profiles of two ultra-long-acting basal 
insulin analogs. They elegantly explain why these therapies are 
likely to offer improved clinical outcomes. Longer-acting and 
peak-less insulin profiles provides equivalent (and probably 
superior) glycaemic control with significantly less attendant 
hypoglycaemia (overall, severe and nocturnal). Soliman N et al 
indicate that cellular damage as indicated by increased DNA 
fragmentation is evident in diabetic patients with nephropathy 
making this measurement a potentially useful clinical tool 
(as a predictive marker of renal damage). Despite its benefits 
lifestyle intervention remains an elusive management strategy 
as dietary and exercise compliance remains a major therapeutic 
challenge in patients with diabetes. Thus Birkenshaw A et al, 
using the SEMDSA guidelines as the yardstick to achieve, report 
that in a cohort of diabetic patients the prevalence obesity was 
extremely high (66%) and this was associated with suboptimal 
dietary practice as measured by total daily caloric intake (too 
much), carbohydrate (too little), fat (too much) and salt intake 
(too much) with inadequate energy expenditure (too little 
exercise). Lifestyle recommendations continue to stubbornly 
evade effective implementation. Lastly Zorgani A et al, review 
their experience of patients with phaeochromocytomas. Unique 
to this local report are data that reflect the clinical characteristics 
and outcomes of patients with large tumours. 
Happy reading and consider Endocrinology with SEMDSA in 
December in Cape Town in 2018.
Jeffrey  Wing
